Table 6.
FDA-approved therapeutic drugs for urologic cancers
| Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
| Aldesleukin (Proleukin) | Chiron | Recombinant human interleukin-2 | Metastatic RCC | 05/05/1992 | O |
| Sorafenib toylate (Nexavar) | Bayer | Multitarget TKI (VEGFR2/3, PDGFRβ, FLT3, KIT, RAF1, and BRAF) | Advanced RCC | 12/01/2005 | P, O |
| Pazopanib HCl (Votrient) | Novartis | Multitarget TKI (VEGFRs, PDGFRα/β, FGFR1/2, KIT) | Metastatic RCC | 10/19/2009 | S |
| Axitinib (Inlyta) | Pfizer | VEGFRs inhibitor | Advanced RCC | 01/27/2012 | S |
| Tivozanib HCl (Fotivda) | Aveo Pharms | VEGFRs inhibitor | Advanced RCC | 03/10/2021 | S |
| Temsirolimus (Torisel) | Merck & Co | mTOR inhibitor | Advanced RCC | 05/30/2007 | P |
| Everolimus (Afinitor) | Novartis | mTOR inhibitor | Advanced RCC | 03/30/2009 | P |
| Atezolizumab (Tecentriq) | Genentech | PDL1-directed mAb | Urothelial carcinoma | 05/18/2016 | N/A |
| Durvalumab (Imfinzi) | AstraZeneca | PDL1-directed mAb | Urothelial carcinoma | 05/01/2017 | N/A |
| Enfortumab vedotin (Padcev) | Astellas | Nectin-4-directed ADC | Urothelial carcinoma | 12/18/2019 | P |
| Valrubicin (Valstar) | Endo Pharm | A semisynthetic analog of anthracycline doxorubicin | BCG-refractory CIS of urinary bladder cancer | 09/25/1998 | P, O |
| Erdafitinib (Balversa) | Janssen | FGFR inhibitor | Bladder cancer | 04/12/2019 | P |
BCG Bacillus Calmette-Guérin; CIS Carcinoma in situ; FGFR Fibroblast growth factor receptor; mTOR Mammalian target of rapamycin; O Orphan; P Priority; PDGFR Platelet-derived growth factor receptor; PDL1 Programmed death-ligand 1; RCC Renal cell carcinoma; S Standard; VEGFR Vascular endothelial growth factor receptor